The effects of magnesium sulfate therapy after severe diffuse axonal injury

Ling Zhao, Wei Wang, Jiwen Zhong, YaYun Li, YanZi Cheng, Zhenjiao Su, Wei Zheng, Xiang-Dong Guan, Ling Zhao, Wei Wang, Jiwen Zhong, YaYun Li, YanZi Cheng, Zhenjiao Su, Wei Zheng, Xiang-Dong Guan

Abstract

Purpose: To evaluate the clinical effects of magnesium sulfate in the treatment of diffuse axonal injury (DAI).

Patients and methods: This study was a randomized, double-blind, placebo-controlled trial conducted in the First Affiliated Hospital of Sun Yat-sen University, Guangzhou and Zhuhai People's Hospital, Zhuhai, two trauma center hospitals. A total of 128 patients suffered from DAI, with initial Glasgow coma scale (GCS) scores of 3-8. They were randomly divided into two groups: magnesium sulfate treatment (MST) group (n=64) and control group (n=64). The MST group received 250 μmol/kg magnesium sulfate intravenously 20 minutes after admission, followed by 750 μmol/kg magnesium sulfate intravenously daily for 5 days. The control group received standard management without MST. GCS scores and serum neuron-specific enolase values were measured and recorded at admission, and on days 3 and 7 after injury. Outcomes were determined by Glasgow outcome scale scores at discharge and at 3 months' follow-up, respectively.

Results: After the 7-day treatment, patients in the MST group, compared with those in the control group, had a lower serum neuron-specific enolase level (25.40±6.66 vs 29.58±7.32, respectively, P=0.001) and higher GCS score (8.23±2.72 vs 7.05±2.64, respectively, P=0.016). Although the length of stay and mortality did not differ between the groups in the intensive care unit, Glasgow outcome scale score was significantly lower in the MST group at discharge (3.30±1.35 vs 3.90±1.10, P=0.004) and 3 months after discharge (2.95±1.48 vs 3.66±1.44, P=0.009).

Conclusion: Early treatment with magnesium sulfate resulted in a significant improvement in DAI outcome. Further studies are needed to confirm the clinical significance of treatment of DAI patients with magnesium sulfate.

Keywords: diffuse axonal injury; magnesium sulfate; outcome.

Figures

Figure 1
Figure 1
Flow chart of the study. Abbreviations: DAI, diffuse axonal injury; MST, magnesium sulfate treatment.
Figure 2
Figure 2
The distribution of the two groups in the different prognosis at discharge. Abbreviations: GOS, Glasgow outcome scale; MST, magnesium sulfate treatment.
Figure 3
Figure 3
The distribution of the groups in the different prognosis after 3 months. Abbreviations: GOS, Glasgow outcome scale; MST, magnesium sulfate treatment.
Figure 4
Figure 4
Comparison of the survival between the two groups at discharge. Abbreviations: CI, confidence interval; MST, magnesium sulfate treatment; P, P-value; HR, hazard rate ratio; B, regression coefficient.
Figure 5
Figure 5
Comparison of the survival between the two groups after 3 months. Abbreviations: CI, confidence interval; MST, magnesium sulfate treatment; P, P-value; HR, hazard rate ratio; B, regression coefficient.

References

    1. Adams JH, Doyle D, Ford I, Gennarelli TA, Graham DI, McLellan DR. Diffuse axonal injury in head injury: definition, diagnosis and grading. Histopathology. 1989;15(1):49–59.
    1. Moen KG, Brezova V, Skandsen T, Håberg AK, Folvik M, Vik A. Traumatic axonal injury: the prognostic value of lesion load in corpus callosum, brain stem, and thalamus in different magnetic resonance imaging sequences. J Neurotrauma. 2014;31(17):1486–1496.
    1. Christman CW, Grady MS, Walker SA, Holloway KL, Povlishock JT. Ultrastructural studies of diffuse axonal injury in human. J Neurotrauma. 1994;11(2):173–186.
    1. Maqnoni S, Esparza TJ, Conte V, et al. Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain. 2012;135(4):1268–1280.
    1. Kara H, Bayir A, Ak A, et al. Trauma in elderly patients evaluated in a hospital emergency department in Konya, Turkey: a retrospective study. Clin Interv Aging. 2014;9:17–21.
    1. Gennarelli TA. Animate models of human head injury. J Neurotrauma. 1994;11(4):357–368.
    1. Marinov MB, Harbaugh KS, Hoopes PJ, Pikus HJ, Harbaugh RE. Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg. 1996;85(1):117–124.
    1. Heath DL, Vink R. Traumatic brain axonal injury produces sustained decline in intracellular free magnesium concentration. Brain Res. 1996;738(1):150–153.
    1. Gee JB, 2nd, Corbett RJ, Perlman JM, Garcia D, Laptook AR. Age-dependent differences in the relationship between plasma and brain extracellular fluid concentrations of magnesium after MgSO4 infusions in miniswine. Pediatr Res. 1999;46(3):281–286.
    1. Vennemeyer JJ, Hopkins T, Kuhlmann J, Heineman WR, Pixley SK. Effects of elevated magnesium and substrate on neuronal numbers and neurite outgrowth of neural stem/progenitor cells in vitro. Neurosci Res. 2014;84:72–78.
    1. Wang WP, Dong JJ. A clinical study on hypothermia treatment for severe diffuse axonal injury. Chin J Traumatol. 2002;18:415–417.
    1. Marion DW, White MJ. Treatment of experimental brain injury with moderate hypothermia and 21-aminosteriods. J Neurotrauma. 1996;13(3):139–147.
    1. Feldman Z, Gurevitch B, Artru AA, et al. Effect of magnesium given 1 hour after head trauma on brain edema and neurological outcome. J Neurosurg. 1996;85(1):131–137.
    1. Mata-Mbemba D, Mugikura S, Nakagawa A, et al. Intraventricular hemorrhage on initial computed tomography as marker of diffuse axonal injury after traumatic brain injury. J Neurotrauma. 2014;32(5):359–365.
    1. Povlishock JT. Traumatically induced axonal injury: pathogenesis and pathobiological implications. Brain Pathol. 1992;2(1):1–12.
    1. Weeks D, Sullivan S, Kilbaugh T, Smith C, Margulies SS. Influences of developmental age on the resolution of diffuse traumatic intracranial hemorrhage and axonal injury. J Neurotrauma. 2014;31(2):206–214.
    1. McDonald JW, Silverstein FS, Johnston MV. Magnesium reduces N-methyl-D-aspartate (NMDA)-mediated brain injury in perinatal rats. Neurosci Lett. 1990;109(1–2):234–238.
    1. Vink R, O’Connor CA, Nimmo AJ, Heath DL. Magnesium attenuates persistent functional deficits following diffuse traumatic brain injury in rats. Neurosci Lett. 2003;336(1):41–44.
    1. Heath DL, Vink R. Improved motor outcome in response to magnesium therapy received up to 24 hour after traumatic diffuse axonal brain injury in rats. J Neurosurg. 1999;90(3):504–509.
    1. Rowe WJ. Correcting magnesium deficiencies may prolong life. Clin Interv Aging. 2012;7:51–54.
    1. Clerc P, Young CA, Bordt EA, Grigore AM, Fiskum G, Polster BM. Magnesium sulfate protects against the bioenergetic consequences of chronic glutamate receptor stimulation. PLoS One. 2013;8(11):e79982.
    1. Altura BM, Barbour RL, Dowd TL, Wu F, Altura BT, Gupta RK. Low extracellular magnesium induces intracellular free Mg deficits, ischemia, depletion of high-energy phosphates and cardiac failure in intact working rat hearts: a 31P-NMR study. Biochim Biophys Acta. 1993;1182(3):329–332.
    1. Stys PK, Ransom BR, Waxman SG. Effects of polyvalent cations and dihydropyridine calcium channel blockers on recovery of CNS white matter from anoxia. Neurosci Lett. 1990;115(2–3):293–299.
    1. Muir KW, Lees KR. Dose optimization of intravenous magnesium sulfate after acute stroke. Stroke. 1998;29(5):918–923.
    1. Hoane MR. Assessment of cognitive function following magnesium therapy in the traumatically injured. Magnes Res. 2007;20(4):229–236.
    1. Hoane MR. Treatment with magnesium improves reference memory but not working memory while reducing GFAP expression following traumatic brain injury. Restor Neurol Neurosci. 2005;23(2):67–77.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться